Earnings Call · Q2 FY2021·2021-08-05

Q2 21EPS -65.57%·Rev n/aQ1 21EPS -4.55%·Rev n/aQ4 20EPS -13.11%·Rev n/aQ3 20EPS +17.54%·Rev n/a⚠ consensus missing

Intellia Therapeutics, Inc. NTLA

Ian Karp — Head of Investor Relations

John Leonard — Chief Executive Officer

David Lebwohl — Chief Medical Officer

Laura Sepp-Lorenzino — Chief Scientific Officer

Glenn Goddard — Chief Financial Officer

+12.4%1d on move date+11.8% vs SPY3d+9.1%5d+8.7%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NTLA calls or request research access.

More NTLA calls Browse calls Request research access